CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced the appointment of Kaveri Parker, Ph.D. as Chief Business Officer. In her role, she will lead the business development and commercialization of Synedgen’s inflammatory and infectious disease programs as well as advance strategic partnership opportunities across Synedgen’s wound care product portfolio. Dr. Parker will also assist with business development for the Prisyna oral care division of Synedgen.
“Kaveri is an accomplished business executive with a deep scientific background and we are thrilled to welcome her to our team,” said Shenda Baker, Ph.D., President and Chief Operating Officer of Synedgen. “Her scientific training and business development experience along with her keen and rapid assessment of market opportunity and positioning will play a critical role in our growth strategy as we continue to develop our product portfolio.”
“Synedgen’s glycomics technology platform has the potential to fundamentally change how we treat infectious and inflammatory diseases,” said Dr. Parker. “I am excited to join Synedgen at a pivotal point in this organization’s growth and look forward to working with the accomplished management team to bring several FDA-cleared products to market and leverage our existing technologies for sustained growth.”
With SynePureTM Wound Cleanser and CatasynTM Advanced Technology Wound Hydrogel having received FDA clearance for marketing, Synedgen Wound Care is a leader in applying glycomics to manage and improve wound care. Synedgen Wound Care products are developed to support a healthy environment for healing without the use of harsh chemicals that can cause further pain and inflame damaged tissue.
Prisyna, the oral care division of Synedgen, has received FDA clearance to market Moisyn® to treat symptoms of dry mouth, which adds to the portfolio including Synedent® and Synedent FLX® oral rinses. The goal of Prisyna’s scientifically-driven formulations is to develop oral health care products that clean the mouth, reduce pain and irritation on sensitive mucosal surfaces and improve overall oral health.
Synedgen has other programs in early development that use the company’s glycomics platform in therapeutics to:
- reduce damage and inflammation due to chemical, radiological or physical damage,
- manage infection, inflammation and ulcers in the gastrointestinal tract,
- target the host-pathogen interface utilizing novel mechanisms to reduce the challenge of antibiotic resistance, and
- provide a barrier to infection and improved healing in the eyes.
Dr. Parker has an extensive background in biochemistry and infectious diseases, as well as years of business development and management experience. Most recently, she served as President and Chief Executive Officer of ID Genomics where she led all aspects of executive management, including investor and media relations, management and scientific team building, strategic and tactical planning, fundraising, and path-to-market strategy. During her tenure, she secured strategic partnerships with 12 major clinical hospital networks across the U.S. and managed ID Genomics’ regulatory and intellectual property development. Prior to her tenure as President and Chief Executive Officer at ID Genomics, she served as Director of Operations. Dr. Parker earned her Ph.D. in biochemistry at Washington University and a Bachelor of Science in biochemistry at the University of New Mexico.
Synedgen is developing a new class of health care products based on glycomics, a revolutionary approach using glycopolymers to target mucosal and dermal interfaces. Synedgen uses its Glycomics Technology Platform (GTP) to discover and develop ultra-purified glycopolymers that enhance and mimic the innate immune system by targeting the cell surface glycocalyx and mucosal surfaces. Synedgen has successfully leveraged the GTP to develop marketed Prisyna oral care and Synedgen wound care products, as well as SNSP113, which has been licensed to Synspira and is currently in clinical development for the treatment of cystic fibrosis. Synedgen has established research and manufacturing facilities in Claremont, California. http://www.synedgen.com/